Follicular thyroid cancer: lines of therapy
4 standard-of-care settings across 3 lines and 2 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
Advanced, first line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Widely invasive or metastatic | Total thyroidectomy, radioactive iodine, TSH suppression; bone metastases may need surgery or radiotherapy. | 84 |
Third line and beyond
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| FRα | Iodine-refractory | Lenvatinib or sorafenib; clinical trials of redifferentiation. | 91 |
Other settings
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Indeterminate follicular nodule | Molecular testing of the aspirate; diagnostic lobectomy when suspicious. | - | ||
| All comers | Minimally invasive | Lobectomy alone in most cases; completion surgery and iodine only for high-risk features. | - |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.